Anixa Biosciences secured a six-month exclusive right to negotiate a deal for VERDI's cancer vaccines. VERDI’s AI-driven platform develops personalized and off-the-shelf peptide vaccines for ...
On Tuesday, Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI ...